Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple costimulatory modalities enhance CTL avidity.

James W Hodge1, Mala Chakraborty, Chie Kudo-Saito

  • 1Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|May 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

Journal for immunotherapy of cancer·2026
Same author

Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models.

Frontiers in immunology·2026
Same author

Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancer.

Nature communications·2026
Same author

Curability difference between autochthonous mouse tumors and their transplants in association with immune gene expression.

PloS one·2026
Same author

IL10RB expression in cancer cells is associated with evolutionary changes to solidify treatment resistance.

BJC reports·2026
Same author

ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Cancer research communications·2026

Enhancing T cell avidity is crucial for effective antitumor and antiviral immunity. This study shows that combining vaccine strategies significantly boosts T cell avidity and antitumor effects.

Area of Science:

  • Immunology
  • Vaccinology
  • Cancer Research

Background:

  • T cell avidity is a critical factor in antitumor and antiviral immunity.
  • Optimizing vaccine strategies to enhance T cell avidity is essential for improving immune responses.

Purpose of the Study:

  • To evaluate various vaccine strategies for their ability to enhance both the quantity and avidity of cytotoxic T lymphocyte (CTL) responses.
  • To assess the impact of different immunogens and costimulatory molecules on T cell avidity and function.

Main Methods:

  • Measured CD8(+) T cell quantity via tetramer binding precursor frequency.
  • Assessed T cell avidity using tetramer dissociation and quantitative cytolytic assays.
  • Evaluated peptide, viral vector, costimulatory molecules (B7-1, ICAM-1, LFA-3), anti-CTLA-4 mAb, and GM-CSF in foreign and self-antigen models.

Related Experiment Videos

Main Results:

  • Combined vaccine strategies significantly enhanced T cell quantity and, to a greater extent, T cell avidity.
  • Combination strategies demonstrated enhanced antitumor effects in relevant mouse models.
  • Specific combinations of costimulatory molecules and immunogens proved most effective.

Conclusions:

  • Multiple vaccine strategies can be combined to generate high-avidity T cell responses.
  • These strategies are applicable to both antitumor and antiviral vaccine development.
  • Enhancing T cell avidity is a viable approach for improving vaccine efficacy.